A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

Recruiting now · Phase 1

Conditions studied: Locally Advanced (Unresectable) or Metastatic Solid Tumors

In brief

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Key facts

Study ID

NCT07612189

Run by

NEOK Bio, Inc.

People needed

155

Starts

2026-04-22

Expected to finish

2029-02-01

Last updated by the study team

2026-06-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• NEXT Oncology — San Antonio, Texas, United States (enrolling)
• SCRI Oncology Partners — Nashville, Tennessee, United States
• NEXT Oncology — Austin, Texas, United States
• NEXT Oncology — Dallas, Texas, United States
• MD Anderson Cancer Center — Houston, Texas, United States
• NEXT Oncology — Houston, Texas, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• NEXT Oncology — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.